Super-enhancer–driven transcription machinery

Super-enhancer–driven transcription machinery refers to the dense collection of transcription factors, coactivators, and chromatin regulators that assemble at super-enhancers (SEs) to drive robust gene expression (Hnisz et al., 2013, Cell). SEs are large clusters of enhancers characterized by high levels of histone H3 lysine 27 acetylation (H3K27ac) and the binding of master regulators like Mediator and BRD4 (Lovén et al., 2013, Cell). In cancer, these structures are often hijacked to drive the disproportionate expression of key oncogenes, such as MYC, which are essential for tumor cell survival and identity (Bradner et al., 2017, Cell). Because SE-driven genes are hypersensitive to the loss of transcriptional components compared to genes driven by typical enhancers, this machinery has become a major therapeutic target. Drugs such as BET inhibitors and transcriptional CDK inhibitors (e.g., targeting CDK7 or CDK9) aim to selectively collapse these transcriptional hubs, which may involve the disruption of phase-separated condensates (Sabari et al., 2018, Science). This selective inhibition leads to the downregulation of oncogenic drivers while potentially sparing normal cellular functions.

Other names

Super-enhancer complexSE-associated transcriptional apparatusTranscriptional regulatory complexSuper-enhancer-mediated transcriptionSE-driven transcription

Disruption of the assembly and activity of transcriptional complexes at super-enhancer sites through the inhibition of BET proteins (e.g., BRD4) or transcriptional cyclin-dependent kinases (e.g., CDK7, CDK9).